Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented... by Laia Bertran (3685147)

Coverage of plant species in each plot. by Xuemei Xiang (20756894)

Subjects:

Specifications and effects of heating devices. by Xuemei Xiang (20756894)

Subjects:

Pan-cancer analyses of ACADM expression and its prognostic significance in the TCGA database. by Yu Zhang (12946)

Subjects:

Additional file 1 of Short-term oral zinc supplementation enhances Natural Killer cell functionality and decreases circulating Innate Lymphoid Cell counts and frequencies in health... by Lara Amling (20882028)

Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients... by Keya Bibikar (22386306)

P values of Kruskal–Wallis test at 95% significance level. by Fahd Saeed Alakbari (10701871)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

Subjects:

<i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

Subjects:

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: